Literature DB >> 19185164

Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer.

Khaled M Sarraf1, Elizabeth Belcher, Evgeny Raevsky, Andrew G Nicholson, Peter Goldstraw, Eric Lim.   

Abstract

OBJECTIVE: Increasing neutrophil/lymphocyte ratios on preoperative blood tests have been associated with worse survival after resection of colorectal cancer. We sought to determine factors associated with increasing neutrophil/lymphocyte ratios and the stage-adjusted prognostic effect in patients undergoing resection for non-small cell lung cancer.
METHODS: We performed a retrospective review of patients undergoing complete resection for non-small cell lung cancer between 1999 and 2005. Data acquisition was through patient medical records, blood results recorded on admission before surgical intervention, and follow-up by National Health Service database searches and hospital records. Cox proportional hazards regression was used to estimate the effect of neutrophil/lymphocyte ratio on stage-adjusted survival.
RESULTS: During the study period, 178 patients underwent pulmonary resection. Of 177 patients, the majority were male 104 (59%), with a mean age of 63 years (standard deviation, 10 years). The median follow-up time was 29 months (interquartile range, 8-56 months), and overall survival was 83% and 54% at 1 and 5 years, respectively. Higher stage was the only factor found to be associated with increasing neutrophil/lymphocyte ratios (P = .019). Total white cell count (P = .990) and neutrophil count (P = .490), age (P = .290), and cell type (P = .490) were not significant predictors of mortality. On multivariable analysis after adjusting for stage, increasing neutrophil/lymphocyte ratios (hazard ratio, 1.10; 95% confidence interval, 1.03-1.17; P = .004) remained an independent prognostic indicator.
CONCLUSIONS: Increasing preoperative neutrophil/lymphocyte ratios are associated with higher stage but remain an independent predictor of survival after complete resection for primary lung cancer and are a potential biomarker to stratify high risk of death in patients with stage I disease.

Entities:  

Mesh:

Year:  2008        PMID: 19185164     DOI: 10.1016/j.jtcvs.2008.05.046

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  213 in total

1.  Difference in survival and prognostic factors between smokers and never-smokers with advanced non-small-cell lung cancer.

Authors:  Shiro Tanaka; Kazuhiro Yanagihara; Satoshi Tamaru; Satoshi Teramukai; Toshiyuki Kitano; Masanori Fukushima
Journal:  Int J Clin Oncol       Date:  2011-11-10       Impact factor: 3.402

2.  Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.

Authors:  Youngjoo Lee; Sun Hye Kim; Ji-Youn Han; Heung Tae Kim; Tak Yun; Jin Soo Lee
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-07       Impact factor: 4.553

3.  Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy.

Authors:  Yue-Can Zeng; Feng Chi; Rui Xing; Ming Xue; Li-Na Wu; Mei-Yue Tang; Rong Wu
Journal:  Jpn J Clin Oncol       Date:  2015-11-25       Impact factor: 3.019

Review 4.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Authors:  Adam J Bograd; Kei Suzuki; Eva Vertes; Christos Colovos; Eduardo A Morales; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-09-13       Impact factor: 6.968

5.  Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting.

Authors:  Young Wha Koh; Hee Jin Lee; Jin-Hee Ahn; Jong Won Lee; Gyungyub Gong
Journal:  Tumour Biol       Date:  2014-07-02

6.  Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.

Authors:  Philipp Nuhn; Ajay M Vaghasia; Jatinder Goyal; Xian C Zhou; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis
Journal:  BJU Int       Date:  2014-02-14       Impact factor: 5.588

7.  Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Eiji Noda; Hiroshi Ohtani; Yukio Nishiguchi; Kosei Hirakawa
Journal:  Surg Today       Date:  2014-05-10       Impact factor: 2.549

8.  Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine.

Authors:  Aaron J Schueneman; Elizabeth A Sugar; Jennifer Uram; Elaine Bigelow; Joseph M Herman; Barish H Edil; Elizabeth M Jaffee; Lei Zheng; Daniel A Laheru
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

9.  Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer.

Authors:  Yeonjoo Choi; Jin Won Kim; Kyung Han Nam; Song-Hee Han; Ji-Won Kim; Sang-Hoon Ahn; Do Joong Park; Keun-Wook Lee; Hye Seung Lee; Hyung-Ho Kim
Journal:  Gastric Cancer       Date:  2016-09-24       Impact factor: 7.370

10.  Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.

Authors:  Oscar Arrieta; Rosa M Michel Ortega; Geraldine Villanueva-Rodríguez; Maria G Serna-Thomé; Diana Flores-Estrada; Consuelo Diaz-Romero; Cindy M Rodríguez; Luis Martínez; Karla Sánchez-Lara
Journal:  BMC Cancer       Date:  2010-02-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.